Annexon, Inc.

Healthcare · Biotechnology · United States

Last price 4.05 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 767.80M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase...